Credit Suisse Keeps a Buy Rating on Alkermes

By Austin Angelo

In a report released yesterday, Vamil Divan from Credit Suisse maintained a Buy rating on Alkermes (NASDAQ: ALKS), with a price target of $70. The company’s shares closed yesterday at $58.99, close to its 52-week high of $62.50.

According to, Divan is a 3-star analyst with an average return of 2.6% and a 51.0% success rate. Divan covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Alder Biopharmaceuticals, and Adamas Pharmaceuticals.

Alkermes has an analyst consensus of Moderate Buy, with a price target consensus of $66.

The company has a one year high of $62.50 and a one year low of $39.65. Currently, Alkermes has an average volume of 812.9K.

Based on the recent corporate insider activity of 107 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALKS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alkermes Plc is a biopharmaceutical company. It engages in the development, manufacturing and distribution of medicines. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.